Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E PIK3CA E545K||lung non-small cell carcinoma||predicted - sensitive||Vemurafenib||Case Reports/Case Series||Actionable||In a clinical study, Zelboraf (vemurafenib) treatment resulted in stable disease for 6.4 months in a non-small cell lung cancer patient harboring BRAF V600E, tested in tissue and plasma, and PIK3CA E545K, tested in plasma only (PMID: 32859654).||32859654|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|